Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
Provided By GlobeNewswire
Last update: Aug 14, 2025
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
Read more at globenewswire.com
